11 June 2021 | News
Aviptadil has shown significant results in clinical trials against COVID-19
Hyderabad-based Biophore India Pharmaceuticals has applied for DCGI emergency use approval of Aviptadil Inhalation for marketing in India, which helps treat moderate to severe cases of COVID-19. Biophore has successfully developed Aviptadil and is backward integrated with in-house API. The company has also informed that it will be commencing commercial production immediately after the approval is received.
Aviptadil is a synthetic form of Vasoactive Intestinal Peptide (VIP) that, when administered, results in rapid clinical recovery in patients with severe SARS-COV-2 infection. These observations are based on results of multiple trials of Aviptadil against COVID-19 globally in patients with respiratory failure and the same has been submitted to DCGI for their review.
Dr Jagadeesh Babu Rangisetty, CEO, Biophore, says, “Biophore has developed this highly complex peptide in a very short period, primarily due to the extensive focus of the company in prioritising COVID related products over the last one year. Aviptadil is a promising treatment option for COVID, especially in severe hospitalised cases where trials have shown a high recovery percentage and we hope to be able to quickly make it available through this approval.”